Harbin Pharmaceutical Group Co Ltd (600664) - Net Assets

Latest as of September 2025: CN¥6.41 Billion CNY ≈ $937.66 Million USD

Based on the latest financial reports, Harbin Pharmaceutical Group Co Ltd (600664) has net assets worth CN¥6.41 Billion CNY (≈ $937.66 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥14.08 Billion ≈ $2.06 Billion USD) and total liabilities (CN¥7.67 Billion ≈ $1.12 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 600664 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥6.41 Billion
% of Total Assets 45.51%
Annual Growth Rate 7.78%
5-Year Change 52.67%
10-Year Change -18.63%
Growth Volatility 17.23

Harbin Pharmaceutical Group Co Ltd - Net Assets Trend (1993–2024)

This chart illustrates how Harbin Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Harbin Pharmaceutical Group Co Ltd for the complete picture of this company's asset base.

Annual Net Assets for Harbin Pharmaceutical Group Co Ltd (1993–2024)

The table below shows the annual net assets of Harbin Pharmaceutical Group Co Ltd from 1993 to 2024. For live valuation and market cap data, see market cap of Harbin Pharmaceutical Group Co Ltd.

Year Net Assets Change
2024-12-31 CN¥6.09 Billion
≈ $891.05 Million		 +12.29%
2023-12-31 CN¥5.42 Billion
≈ $793.53 Million		 +9.53%
2022-12-31 CN¥4.95 Billion
≈ $724.49 Million		 +12.00%
2021-12-31 CN¥4.42 Billion
≈ $646.86 Million		 +10.83%
2020-12-31 CN¥3.99 Billion
≈ $583.65 Million		 -32.88%
2019-12-31 CN¥5.94 Billion
≈ $869.62 Million		 -5.38%
2018-12-31 CN¥6.28 Billion
≈ $919.10 Million		 -16.05%
2017-12-31 CN¥7.48 Billion
≈ $1.09 Billion		 -9.84%
2016-12-31 CN¥8.30 Billion
≈ $1.21 Billion		 +10.89%
2015-12-31 CN¥7.48 Billion
≈ $1.09 Billion		 -14.68%
2014-12-31 CN¥8.77 Billion
≈ $1.28 Billion		 -0.03%
2013-12-31 CN¥8.77 Billion
≈ $1.28 Billion		 +1.40%
2012-12-31 CN¥8.65 Billion
≈ $1.27 Billion		 +34.91%
2011-12-31 CN¥6.41 Billion
≈ $938.47 Million		 -2.02%
2010-12-31 CN¥6.55 Billion
≈ $957.81 Million		 +9.38%
2009-12-31 CN¥5.98 Billion
≈ $875.69 Million		 +3.38%
2008-12-31 CN¥5.79 Billion
≈ $847.08 Million		 +14.54%
2007-12-31 CN¥5.05 Billion
≈ $739.58 Million		 +1.81%
2006-12-31 CN¥4.96 Billion
≈ $726.45 Million		 +13.02%
2005-12-31 CN¥4.39 Billion
≈ $642.77 Million		 +12.45%
2004-12-31 CN¥3.91 Billion
≈ $571.61 Million		 +24.82%
2003-12-31 CN¥3.13 Billion
≈ $457.96 Million		 +8.73%
2002-12-31 CN¥2.88 Billion
≈ $421.18 Million		 +7.48%
2001-12-31 CN¥2.68 Billion
≈ $391.86 Million		 +64.76%
2000-12-31 CN¥1.63 Billion
≈ $237.84 Million		 +10.11%
1999-12-31 CN¥1.48 Billion
≈ $216.01 Million		 +16.10%
1998-12-31 CN¥1.27 Billion
≈ $186.06 Million		 +13.72%
1997-12-31 CN¥1.12 Billion
≈ $163.60 Million		 +41.71%
1996-12-31 CN¥788.98 Million
≈ $115.45 Million		 +17.39%
1995-12-31 CN¥672.12 Million
≈ $98.35 Million		 +5.26%
1994-12-31 CN¥638.52 Million
≈ $93.44 Million		 +7.11%
1993-12-31 CN¥596.14 Million
≈ $87.23 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Harbin Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 2454.6% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥2.63 Billion 49.07%
Common Stock CN¥2.52 Billion 47.08%
Other Comprehensive Income CN¥-68.99 Million -1.29%
Other Components CN¥274.91 Million 5.14%
Total Equity CN¥5.35 Billion 100.00%

Harbin Pharmaceutical Group Co Ltd Competitors by Market Cap

The table below lists competitors of Harbin Pharmaceutical Group Co Ltd ranked by their market capitalization.

Company Market Cap
Sichuan Crun Co Ltd
SHE:002272
 $1.39 Billion
Jiangsu SOPO Chemical Co Ltd
SHG:600746
 $1.39 Billion
Nanobiotix S.A
PA:NANO
 $1.39 Billion
Shenzhen Baoming Technology Co
SHE:002992
 $1.39 Billion
Beijing Cuiwei Tower Co Ltd
SHG:603123
 $1.39 Billion
Kingenta Ecological Engineering Group Co Ltd
SHE:002470
 $1.38 Billion
HeBei Jinniu Chemical Industry Co Ltd
SHG:600722
 $1.38 Billion
Jiangsu Jiuding New Material Co Ltd
SHE:002201
 $1.38 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Harbin Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 4,724,089,680 to 5,349,779,547, a change of 625,689,867 (13.2%).
  • Net income of 628,846,606 contributed positively to equity growth.
  • Dividend payments of 47,106,203 reduced retained earnings.
  • Share repurchases of 3,982,526 reduced equity.
  • Other comprehensive income increased equity by 825,794.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥628.85 Million +11.75%
Dividends Paid CN¥47.11 Million -0.88%
Share Repurchases CN¥3.98 Million -0.07%
Other Comprehensive Income CN¥825.79K +0.02%
Other Changes CN¥47.11 Million +0.88%
Total Change CN¥- 13.24%

Book Value vs Market Value Analysis

This analysis compares Harbin Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.77x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 16.00x to 1.77x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1993-12-31 CN¥0.23 CN¥3.76 x
1994-12-31 CN¥0.25 CN¥3.76 x
1995-12-31 CN¥0.27 CN¥3.76 x
1996-12-31 CN¥0.31 CN¥3.76 x
1997-12-31 CN¥0.44 CN¥3.76 x
1998-12-31 CN¥0.50 CN¥3.76 x
1999-12-31 CN¥0.70 CN¥3.76 x
2000-12-31 CN¥0.77 CN¥3.76 x
2001-12-31 CN¥1.26 CN¥3.76 x
2002-12-31 CN¥1.34 CN¥3.76 x
2003-12-31 CN¥1.45 CN¥3.76 x
2004-12-31 CN¥1.61 CN¥3.76 x
2005-12-31 CN¥1.84 CN¥3.76 x
2006-12-31 CN¥2.07 CN¥3.76 x
2007-12-31 CN¥2.40 CN¥3.76 x
2008-12-31 CN¥2.74 CN¥3.76 x
2009-12-31 CN¥2.84 CN¥3.76 x
2010-12-31 CN¥3.10 CN¥3.76 x
2011-12-31 CN¥2.54 CN¥3.76 x
2012-12-31 CN¥3.18 CN¥3.76 x
2013-12-31 CN¥3.35 CN¥3.76 x
2014-12-31 CN¥3.33 CN¥3.76 x
2015-12-31 CN¥2.80 CN¥3.76 x
2016-12-31 CN¥3.09 CN¥3.76 x
2017-12-31 CN¥2.77 CN¥3.76 x
2018-12-31 CN¥2.37 CN¥3.76 x
2019-12-31 CN¥1.96 CN¥3.76 x
2020-12-31 CN¥1.39 CN¥3.76 x
2021-12-31 CN¥1.53 CN¥3.76 x
2022-12-31 CN¥1.68 CN¥3.76 x
2023-12-31 CN¥1.91 CN¥3.76 x
2024-12-31 CN¥2.13 CN¥3.76 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Harbin Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 11.75%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 3.89%
  • • Asset Turnover: 1.11x
  • • Equity Multiplier: 2.73x
  • Recent ROE (11.75%) is above the historical average (9.20%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1993 23.21% 5.86% 1.05x 3.78x CN¥78.23 Million
1994 15.90% 5.74% 0.75x 3.70x CN¥37.45 Million
1995 16.35% 5.36% 0.85x 3.59x CN¥42.40 Million
1996 14.32% 5.15% 0.88x 3.17x CN¥33.94 Million
1997 10.83% 5.31% 0.78x 2.60x CN¥9.23 Million
1998 7.70% 3.34% 0.81x 2.85x CN¥-29.12 Million
1999 9.42% 3.09% 1.02x 3.00x CN¥-8.49 Million
2000 13.48% 3.38% 1.45x 2.76x CN¥56.20 Million
2001 10.73% 5.29% 0.93x 2.18x CN¥19.26 Million
2002 10.73% 4.63% 1.09x 2.12x CN¥20.46 Million
2003 10.91% 4.78% 1.05x 2.16x CN¥27.51 Million
2004 7.77% 3.67% 0.96x 2.21x CN¥-75.40 Million
2005 11.84% 5.37% 0.98x 2.24x CN¥70.73 Million
2006 10.78% 5.04% 0.99x 2.17x CN¥33.66 Million
2007 11.73% 7.14% 0.88x 1.87x CN¥87.16 Million
2008 14.90% 8.89% 1.00x 1.67x CN¥283.75 Million
2009 15.60% 8.74% 1.07x 1.67x CN¥334.88 Million
2010 17.36% 9.02% 1.07x 1.81x CN¥479.23 Million
2011 9.08% 4.31% 1.15x 1.83x CN¥-58.89 Million
2012 6.28% 2.83% 1.13x 1.97x CN¥-296.00 Million
2013 2.07% 0.93% 1.10x 2.02x CN¥-646.32 Million
2014 3.00% 1.50% 1.02x 1.97x CN¥-576.71 Million
2015 8.23% 3.66% 1.15x 1.95x CN¥-125.15 Million
2016 10.04% 5.58% 0.94x 1.92x CN¥2.86 Million
2017 5.77% 3.39% 0.88x 1.94x CN¥-298.18 Million
2018 5.90% 3.20% 0.91x 2.03x CN¥-240.40 Million
2019 1.02% 0.47% 0.95x 2.29x CN¥-489.84 Million
2020 -30.97% -9.99% 0.91x 3.40x CN¥-1.43 Billion
2021 9.65% 2.90% 1.00x 3.34x CN¥-13.64 Million
2022 10.74% 3.37% 1.03x 3.10x CN¥32.04 Million
2023 8.37% 2.56% 1.10x 2.99x CN¥-77.15 Million
2024 11.75% 3.89% 1.11x 2.73x CN¥93.87 Million

Industry Comparison

This section compares Harbin Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $3,517,854,642
  • Average return on equity (ROE) among peers: 7.81%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Harbin Pharmaceutical Group Co Ltd (600664) CN¥6.41 Billion 23.21% 1.20x $1.39 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $205.69 Million 15.10% 2.12x $1.05 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $765.24 Million 1.30% 0.72x $438.59 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $1.12 Billion 13.25% 0.26x $5.06 Billion
Livzon Pharmaceutical Group Inc (000513) $1.01 Billion 1.03% 0.58x $2.76 Billion
Wedge Industrial Co Ltd (000534) $551.68 Million 1.40% 0.01x $2.94 Billion
Yunnan Baiyao Group Co Ltd (000538) $740.30 Million 23.15% 0.72x $13.74 Billion
Hainan Haiyao Co Ltd (000566) $317.39 Million 7.74% 0.74x $958.72 Million
Tus Pharmaceutical Group Co Ltd (000590) $271.26 Million 1.07% 1.01x $386.52 Million
Northeast Pharmaceutical Group Co Ltd (000597) $5.16 Billion 6.95% 1.96x $1.04 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $25.04 Billion 7.11% 0.16x $3.29 Billion

About Harbin Pharmaceutical Group Co Ltd

SHG:600664 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.39 Billion
CN¥9.47 Billion CNY
Market Cap Rank
#7785 Global
#1957 in China
Share Price
CN¥3.76
Change (1 day)
+2.73%
52-Week Range
CN¥3.23 - CN¥4.44
All Time High
CN¥8.34
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cere… Read more